Literature DB >> 3149927

In vitro synergy studies with ciprofloxacin and selected beta-lactam agents and aminoglycosides against multidrug-resistant Pseudomonas aeruginosa.

R D Meyer1, S Liu.   

Abstract

In order to determine the effect of combining ciprofloxacin with beta-lactam and aminoglycoside agents against multidrug-resistant P. aeruginosa, ciprofloxacin was tested in vitro with the checkerboard broth microdilution technique with various current beta-lactam and aminoglycoside agents. In both inhibitory and bactericidal testing, the combination of ciprofloxacin with a beta-lactam agent (ceftazidime, piperacillin, mezlocillin, azlocillin, or imipenem) was more likely to show a synergistic effect or additive effect and lack of antagonism (96.5% of all inhibitory and cidal tests) than was a combination of ciprofloxacin with an aminoglycoside [(amikacin, tobramycin, or gentamicin), 90% of all inhibitory and cidal tests]. Finding of antagonism in some testing, especially with aminoglycosides, indicates that results are unpredictable. These results may influence selection of agents for selection in clinical situations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3149927     DOI: 10.1016/0732-8893(88)90017-x

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

1.  Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.

Authors:  Julien M Buyck; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

2.  Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  B Balke; M Hogardt; S Schmoldt; L Hoy; H Weissbrodt; S Häussler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

3.  Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses.

Authors:  Y Q Xiong; L I Kupferwasser; P M Zack; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.